← SynDRA
TUCATINIB
SynDRA canonical compound SYN0039101 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
| Approval status | Approved · Rx |
| Primary target(s) | ERBB2 |
| Mechanism of action | EGFR inhibitor |
All known targets
- ERBB2
- EGFR
- ERBB4
- ERBB3
- FECH
- MYH14
- NQO2
- RIPK3
Mechanisms of action (all sources)
- ERBB2 INHIBITOR
- Receptor protein-tyrosine kinase erbB-2 inhibitor
- EGFR INHIBITOR
- ERBB4 INHIBITOR
- ERBB2 MODULATOR
- ERBB3 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SYK
- AAK1
- NLK
- PHKG2
- PGRMC1
- PFKP
- PEBP1
- PDXK
- PDGFRB
- PCYT1A
- PASK
- PAK4
- PAK2
- PAICS
- OPA1
- OLA1
- NUAK2
- PIM1
- PIP4K2A
- PIP4K2C
- PRKACG
- PRKCD
- PRKCB
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACB
- PKMYT1
- PRKACA
- PRKAA1
- PLK4
- PKN3
- PKN2
- PKN1
- NTRK1
- NEK9
- PRKCQ
- MAPK8
- MARK3
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Antineoplastic Agents
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Tyrosine Kinase Inhibitors
- Kinase Inhibitor
- P-Glycoprotein Inhibitors
- Cytochrome P450 2C8 Inhibitors
- Cytochrome P450 3A Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- TUKYSA
- Tukysa
- tukysa
- ARRY-380
- ONT-380
- Irbinitinib
- MK-7119
- ONT 380
- UNII-234248D0HH
- 234248D0HH
- Tucatinib [USAN:INN]
- 6-DIAMINE
- ARRY-380 Analog
- ARRY-380 (analog )
- UNII-H32S1659ED
- HER2 Inhibitor 1
- H32S1659ED
- SCHEMBL10169911
- C29H27N7O4S
- DTXSID00239555
- MolPort-023-293-540
- HMS3656B04
- BDBM185146
- EX-A1261
- AOB87708
- BCP02833
- ZINC73096245
- 2227AH
- s2752
- AKOS026750520
- CS-0484
- SB16599
- BCP9000319
- NCGC00346672-01
- NCGC00346672-06
- Irbinitinib(ARRY-380)
- Irbinitinib; ARRY-380; ONT-380
- Tucatinib [INN]
Reported adverse events
- Arthralgia
- Epistaxis
- Nausea
- Rash
- Stomatitis
- Vomiting
- Abdominal pain
- Anxiety
- Back pain
- Chills
- Constipation
- Cough
Look up TUCATINIB in the interactive SynDRA portal →